SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Exelixis, Inc. (NASDAQ: EXEL) today announced that the company, along with its partner Ipsen, will host a live briefing event for investors and media to discuss data for cabozantinib presented at the European Society for Medical Oncology (ESMO) 2017 Congress. The webcast event will be held on Sunday, September 10, 2017, beginning at 18:45 CEST (local Madrid time) / 12:45 p.m. EDT / 9:45 a.m. PDT.
During the briefing, Exelixis and Ipsen management and invited guests will discuss and provide context for clinical data for cabozantinib presented at the ESMO 2017 Congress. Exelixis previously announced that cabozantinib will be the subject of eight presentations at the meeting, including a poster discussion on CABOSUN highlighting the progression-free survival analysis by the independent radiology review committee and updated overall survival results. CABOSUN is a phase 2 trial of cabozantinib compared with sunitinib in patients with previously untreated advanced renal cell carcinoma. Updated data from the phase 1 trial evaluating the combination of cabozantinib and nivolumab with or without ipilimumab in patients with metastatic urothelial carcinoma and other genitourinary tumors will be the subject of an oral presentation.
The briefing webcast may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call (855) 793-2457 (domestic) or (631) 485-4921 (international) and provide the conference call passcode 68961937 to join by phone.
A telephone replay will be available until 11:59 p.m. EDT on September 17, 2017. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 68961937. A webcast replay will also be available archived on www.exelixis.com for one year.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors: CABOMETYX® tablets approved for previously treated advanced kidney cancer and COMETRIQ® capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC®, is a formulation of cobimetinib, a reversible inhibitor of MEK, is marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subjects of broad clinical development programs. For more information on Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170906006789/en/
